# 

### **MANAGEMENT & PRACTICE**

THE OFFICIAL MANAGEMENT JOURNAL OF ISICEM VOLUME 16 - ISSUE 1 - SPRING 2016 VISIT US

GISICEM16

#D6-D7

### **PLUS**

**Biomarker Guided Antibiotic Therapy** 

**Lung Protective Ventilation** 

**Medication Safety** 

Frailty in the Critically Ill Patient

**Antimicrobial Copper Touch Surfaces** 

Bedside Ultrasonography in **Critical Care** 

**Transforming Measurement** into Understanding

The Patient and Relative Perspective

**Dietitians in Critical Care** 

A Librarian in the Critical Care Team

**Publiometrics** 

Interview: Prof. Todd Dorman, President, Society of Critical

Care Medicine

**Country Focus: Denmark** 









## J Hanison Consultant in Anaesthetics and Intensive Care Medicine Central Manchester University Hospitals NHS Foundation Trust Manchester, UK

jameshanison@nhs.net



#### **AN Thomas**

Consultant in Anaesthesia and Critical Care Salford Royal NHS Foundation Trust Salford, UK

Chair Greater Manchester Critical Care Network Clinical Effectiveness

tony.thomas@srft.nhs.uk

ll drugs are inherently dangerous. In critical care we give large numbers of particularly dangerous drugs to very sick people, who have little physiological reserve to cope with additional problems. When patients are admitted to or transferred out of critical care we have to transfer complex information about patients' medications. The staff prescribing and administering medications are often inexperienced and working as part of a team that is attempting to communicate information in difficult circumstances. Staff are also dependent on elaborate and sophisticated technology to 'help' them in this process. The complexities of the medication process have also produced some confusing terminology, which is defined in **Table 1**. Faced with these problems we have to do all that we can to minimise the risks associated with medications. We will never make medications completely safe. Medication safety is a continuous process of improvement and learning.

#### **Strategies to Reduce Risk**

Improving medication safety has been the subject of considerable research and investment. Before describing the details of specific actions it is important to note that the general safety culture of a unit will strongly influence patient safety within the unit (Kho et al. 2005). This culture is dependent on the quality of management in the unit (Morello et al. 2013).

## **MEDICATION SAFETY**

Getting management right will be essential in promoting medication safety. There should also be a structured review of all the medications on each consultant ward round, as all medications are potentially dangerous. Structured rounds (Lane et al. 2013) and clear ward round goal setting (Pronovost et al. 2003) are essential preconditions for medication safety.

The effectiveness of specific interventions (**Figure 1**) to improve medication safety has been well reviewed in a recent meta-analysis (Manias et al. 2012). The following interventions have been shown to improve safety:

Involvement of a Pharmacist: The recent core standards issued by the UK Faculty of Intensive Care Medicine (Core Standards Working Party of the Joint Professional Standards Committee 2013) recommend that all critical care units have a competent clinical pharmacist, who will attend consultant ward rounds and be an integrated part of the critical care team. This recommendation is based on evidence (Preslaski et al. 2013; MacLaren et al. 2008). The pharmacist role is relatively new in critical care, and encouraging pharmacists to be fully engaged in ward rounds (Leape et al. 1999) and teaching may be a challenge. A review of the role

## ■ Medication safety is a continuous process of improvement and learning ■ ■

of the critical care pharmacist stresses the cost saving implications as well as the clinical benefits (Weber et al. 2003).

Medicines Reconciliation: Not only are drugs dangerous, but also stopping them precipitously can be harmful, for example beta blockers (Shammash et al. 2001) and statins (Tziomalos et al. 2008). One of the most common prescribing errors identified in a review of patient safety incidents was to prescribe a drug to which the patient was known to be allergic (Thomas and Taylor 2014). Obtaining a drug history in a comatose patient may be challenging, and ensuring all patients have a medicines reconciliation is an organisational challenge. The

reconciliation process should be repeated at transfer from critical care; otherwise patients may continue to receive drugs that were only appropriate for the critical care episode (examples reported as patient safety incidents include proton pump inhibitors, clonidine and steroids). There may also be problems with drugs that have complex dosing protocols, for example insulin, gentamycin and vancomycin. These problems can be controlled by structured handovers at all transfers of care (Segall et al. 2012; Pickering et al. 2009).

Education of Staff: Educational theory is clearly outside the scope of this review, but it should be carefully considered before introducing any educational intervention. Interventions that offer specific feedback to individual prescribers reduce prescribing errors (Thomas et al. 2008), and interventions in the workplace are more effective than didactic lectures (Ford et al. 2010). In Greater Manchester we have introduced a multifaceted educational and audit-based programme to reduce the number of prescriptions of medications to which the patient is known to be intolerant to (Greater Manchester Critical Care & Major Trauma Services Network 2015) (Figure 2). Some education

can be delivered using e-learning, which removes the immediate requirement for an educator and allows monitoring of the resource usage (Thomas 2013; Thomas 2012). The costs of basic provision of e-learning should be affordable for units willing to invest in the material, but this

should be an adjuvant to workplace learning, which does require staff to deliver and receive the training.

#### **Technological Interventions**

There are a number of technological interventions that have not shown a reduction in patient safety incidents associated with their introduction (Manias et al. 2012). Failure to show an improvement in patient safety with these interventions may reflect problems with study design, as the interventions were generally studied within weeks or months after introduction. This time period would not allow units to deal with teething problems associated with introducing



complex technology. Studies also frequently do not describe the complex processes in a unit that should be associated with the introduction of new technology. For example, a study showing lack of benefit with smart pump technology did not use the drug libraries available in the pumps (Rothschild et al 2005). There are also problems with producing interventional studies that are adequately powered to detect reduction in harm when the harm is relatively uncommon (Black 1996).

Examples of technological innovations that have not been proven to improve medication safety include:

**Electronic prescribing:** Electronic prescribing removes many prescribing errors connected with poor handwriting, lost charts and dosing errors, but it allows other errors. Review of patient safety incidents (Thomas and Taylor 2014) suggests the most common problems are associated with the transfer of drug information where a unit uses a different system to the rest of the hospital. Incidents also clearly increase in the time that a new system is introduced, and the introduction of electronic prescribing should be properly supported. There are also ongoing issues with medications discontinuing at their stop dates without being reviewed and drugs remaining on the system after they are no longer required.

Smart pump technology: Pumps that have libraries of drugs that then limit the potential rates of infusion to safe levels, clearly display the drug being infused, and use specific barcoding of syringes so that only the correct drug can be infused, should on face value improve medication safety. Unfortunately there is a lack of evidence for the effectiveness of these interventions (Manias et al. 2012). This lack of evidence may be because, in some studies evaluating this technology, the technology was not actually being used as it should have been (Rothschild et al. 2005). The methods used to introduce this technology are also complex and involve training large numbers of staff. Patient harm associated with mis-setting of pumps is very important for a few patients, but it is difficult to detect a change in the rates of these uncommon events with randomised trials. Regardless of the evidence of benefit, it is clear that manufacturers are going to continue to develop this technology. When choosing this technology it is essential to consider the ergonomic design of the pump to check that staff are going to be able to understand how to use it. It would Table 1. Terminology

Adverse drug events (or adverse drug reactions): events that describe harm suffered by patients as a result of medication use; the harm may be unavoidable. There is often considerable uncertainty about the relationship between an adverse event and a particular drug, and there are tools to assess the probability that the drug and the event are linked (Meyboom et al. 1997). This uncertainty may result in us underestimating the harm associated with medication use.

Medication errors: avoidable actions by staff, which may or may not result in patient harm.

Patient safety incidents (or 'critical' incidents): episodes of harm or potential harm that are self-reported by staff and may or may not have been the result of an 'error'. Patient safety incidents rely on the voluntary reporting of incidents; many incidents may go unreported.

**Global triggers:** adverse events that should prompt a review of medications to see if medication use could have been associated with the adverse event. For example, a very abnormal prothrombin result should be reviewed for potential errors in the prescription or administration of warfarin (Griffin and Resar 2007). Global triggers do not rely on voluntary reporting, but will not capture the broad scope of patient safety incidents. Therefore global triggers and incident reporting should be used together (Stockwell and Kane-Gill 2010).

**High-risk medications:** medications that are commonly associated with patient harm (Institute for Healthcare Improvement 2012). High-risk medications that we should pay particular attention to are insulins, anticoagulants, inotropes, opiates and variable dose antibiotics (for example gentamycin and vancomycin). There is specific guidance around the use of these medications. Training and decision support and protocols of care should first be focused on these drugs.



Figure 1. Strategies to Improve Medication Safety on Critical Care

also be helpful to be able to assess a pump being used in another unit before deciding to purchase it. It is also important to clearly define the assistance the supplier will provide in training and to define how you will introduce the new technology safely.

#### **Causes for Adverse Drug Events**

We have reviewed patient safety incidents reported from most critical care units across the North West of England since 2009, described the broad classification of these incidents (Thomas and Taylor 2012), and reviewed





Figure 2. Part of the Greater Manchester Critical Care Network Educational Programme

incidents specifically associated with medications (Thomas and Taylor 2014). These reviews have shown that medication incidents represent the largest number of incidents that are clearly preventable, and that incidents that are preventable are as likely to be associated with harm as other incidents. The reviews also suggested that the rate of reporting of medication incidents per thousand patient days was ten times higher in some units than other units. This variation seemed to be independent of the type of unit or the network in the North West; significant variation without a clear explanation suggests that there is scope for quality improvement in many units (Tomson and van der Veer 2013). Most incidents associated with patient harm result from problems with the prescription or administration of medicines. With respect to prescription problems the most common problems were not prescribing medications that were indicated, not prescribing according to the British National Formulary and not prescribing according to unit protocols. This suggests that providing drug information to prescribers and improving the provision of information about drugs, particularly information about local protocols, would improve medication safety. The use of forcing functions, for example standard prescriptions, would presumably also help compliance with local protocols. With respect to administration, most common problems were associated with the incorrect checking of medications. This may in part be because

the role of the second checker has not always been clearly defined; without this definition the second checker could result only in causing the first checker to stop concentrating on the checking process (Armitage 2008).

The drugs most commonly involved were drugs already described as high-risk medications, so confirming that efforts to improve medication safety should concentrate on these drugs. With insulin the most common cause of hypoglycaemia was a failure to adjust the insulin infusion rate or provide alternative calories when enteral feed was interrupted (Thomas and Taylor 2014). Incorrect selection of arterial flush solutions with the potential for inaccurate measurement of blood glucose (Leslie et al. 2013) continued to be reported into 2014.

In summary medications are dangerous and should be stopped as soon as they are no longer needed. Reducing harm from medications requires units to develop a safety culture that encourages continual learning from episodes of harm. Improvement requires investment in systems of care and consistent ways of working. The engagement of pharmacists in this process is critical and is more evidence-based than investment in expensive technology.

#### References

Armitage G (2008) Double checking medicines: defence against error or contributory factor? J Eval Clin Pract. 14(4): 513-9.

Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ, 312(7040): 1215-8.

Core Standards Working Party of the Joint Professional Standards Committee (2013) Core standards for intensive care units. London: Faculty of Intensive Care Medicine; Intensive Care Society [Accessed: 11 September 2015] Available from firm ac uk/sites/default/files/Core%20Standards%20for%20ICUs%20Ed.1%20(2013).pdf

Ford DG, Seybert AL, Smithburger PL et al. (2010) Impact of simulation-based learning on medication error rates in critically ill patients. Intensive Care Med, 36(9): 1526-31

Greater Manchester Critical Care & Major Trauma Services Network (2015) Drug allergies. [Accessed: 11 September 2015] Available from gmccn.org.uk/ riconpages/medication-projects/drug-allergies

Griffin FA, Resar RK (2007) IHI global trigger tool for measuring adverse events. IHI Innovation Series white paper. Cambridge, MA: Institute for Healthcare Improvement. [Accessed: 11 September 2015] Available from ihi.org/ resources/pages/ihiwhitepapers/ihiglobaltriggertoolwhitepaper.aspx

How-to guide: prevent harm from high-alert medications cambridge, MA: Institute for Healthcare Improvement, [Accessed: 11 September

2015] Available from ihi.org/resources/Pages/ Morello RT, Lowthian JA, Barker AL et al. (2013) Thomas AN, Boxall EM, Laha SK et al. (2008) An ools/HowtoGuidePreventHarmfromHighAlert-Medications.aspx

Kho ME, Carbone JM, Lucas J et al. (2005) Safety climate survey: reliability of results from multicenter ICU survey. Qual Saf Health Care, 14[4]: 273-8

Lane D. Ferri M, Lemaire J et al. (2013) A systematic review of evidence-informed practices for patient care rounds in the ICU. Crit Care Med, 41[8]: 2015-29

Leape LL, Cullen DJ, Clapp MD et al. [1999] Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 282(3): 267-70.

Management of arterial lines and blood sampling in intensive care: a threat to patient safety. Anaes thesia, 68[11]: 1114-9

MacLaren R, Bond CA, Martin SJ et al. (2008) Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med, 36(12):

Manias E, Williams A, Liew D (2012) Interventions to reduce medication errors in adult intensive care: a systematic review. Br J Clin Pharmacol,

Meyboom RH, Hekster YA, Egberts AC et al. Institute for Healthcare Improvement (2012) [1997] Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf, 17(6): 374-89

Strategies for improving patient safety culture in hospitals: a systematic review. BMJ Qual Saf. 22[1]: 11-8.

Pickering BW. Hurley K. Marsh B (2009) Identification of patient information corruption in the intensive care unit: using a scoring tool to direct quality improvements in handover. Crit academic.org.uk/air embolus/air embolus.swf Care Med, 37(11): 2905-12.

Pharmacist contributions as members of the multidisciplinary ICU team. Chest, 144(5): 1687-95.

Pronovost P, Berenholtz S, Dorman T et al. (2003) Improving communication in the ICU using daily goals. J Crit Care, 18(2): 71-5.

Leslie RA, Gouldson S, Habib N et al. [2013] Rothschild JM, Keohane CA, Cook EF et al. [2005] A controlled trial of smart infusion pumps to improve medication safety in critically ill patients. Crit Care Med. 33(3): 533-40.

> Segall N, Bonifacio AS, Schroeder RA et al. (2012) Can we make postoperative patient handover safer? A systematic review of the literature. Anesth Analg, 115(1): 102-15.

hammash JB, Trost JC, Gold JM et al. [2001] Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J, 141(1): 148-53.

Stockwell DC, Kane-Gill SL (2010) Developing a patient safety surveillance system to identify adverse events in the intensive care unit. Crit Care Med, 38(6 Suppl): S117-25.

educational and audit tool to reduce prescribing error in intensive care. Qual Saf Health Care, 17(5): 360-3.

Thomas AN (2012) Air embolus: a constant threat to the critically ill [online]. [Accessed: 11 September 2015] Available from elearning.hope

Thomas AN (2013) Preventing allergic reactions Preslaski CR, Lat I, MacLaren R et al. (2013) in critical care [online]. [Accessed: 11 September 2015] Available from elearning.hope-academic org.uk/allergicreaction/allergicreactions.htm

> Thomas AN, Taylor RJ (2012) Review of patient safety incidents reported from critical care units in North-West England in 2009 and 2010. Anaesthesia, 67(7): 706-13.

> Thomas AN, Taylor RJ (2014) An analysis of patient safety incidents associated with medications reported from critical care units in the North West of England between 2009 and 2012. Anaesthesia, 69(7): 735-45.

Tomson CR, van der Veer SN (2013) Learning from practice variation to improve the quality of care. Clin Med, 13(1): 19-23

Tziomalos K, Athyros VG, Mikhailidis DP (2008) Statin discontinuation: an underestimated risk? Curr Med Res Opin, 24(11): 3059-62.

Weber RJ, Kane SL, Oriolo VA et al. [2003] Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med, 31(1 Suppl): \$17-24.